Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B

Modern cancer treatment employs many effective chemotherapeutic agents originally discovered from natural sources. However, a significant challenge currently confronting clinical application is balancing systemic toxicity risk with therapeutic benefit. The cyclic depsipeptide didemnin B has demonstr...

Descripción completa

Detalles Bibliográficos
Autores principales: Potts, Malia B., McMillan, Elizabeth A., Rosales, Tracy I., Kim, Hyun Seok, Ou, Yi-Hung, Toombs, Jason E., Brekken, Rolf A., Minden, Mark D., MacMillan, John B., White, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433765/
https://www.ncbi.nlm.nih.gov/pubmed/25867045
http://dx.doi.org/10.1038/nchembio.1797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433765/
https://www.ncbi.nlm.nih.gov/pubmed/25867045
http://dx.doi.org/10.1038/nchembio.1797

Ejemplares similares